Publication
Article
BioPharm International
BioPharm International-12-16-2013Volume2013 eBook Issue 1
Creating Better Medicines through Better Conjugation
Author(s):
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.
Read this articlefrom BioPharm International’s 2013 Innovation Updates and Strategies eBook.
Articles in this issue
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Videos
Related Content
